A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium
Camille Gunderson Jackson, Kathleen N. Moore, Leigh A. Cantrell, Britt Erickson, Linda Duska, Debra L. Richardson, Lisa M. Landrum, Laura L. Holman, Joan L. Walker, Robert S. Mannel, Katherine Moxley, Lurdes Queimado, Andrew J. Cohoon, Kai Ding, Lauren Dockery
Topics & Concepts
MedicineBevacizumabInternal medicineOncologyCervical cancerTolerabilityEndometrial cancerClinical endpointProgression-free survivalPopulationSurvival rateCancerClinical trialChemotherapyAdverse effectEnvironmental healthEndometrial and Cervical Cancer TreatmentsPARP inhibition in cancer therapyChromatin Remodeling and Cancer